Position in SLGL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$37,070,000
-$2,540,000 QoQ
Shares Held
500,000
0.0% QoQ
Ownership
15.3%
of shares outstanding
% of Portfolio
3.40%
of 13F equity value
Holder Rank
#1
of 24 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SLGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Opaleye Management Inc. holds $678,840,611 across 50 Biotechnology names. SLGL ranks #5 (5.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IRON |
Disc Medicine, Inc.
|
855,000 | $62,534,700 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
1,439,996 | $52,991,852 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
|
390,000 | $51,764,700 | |
| 4 | MGTX |
MeiraGTx Holdings plc
|
3,550,000 | $47,960,500 | |
| 5 | SLGL |
Sol-Gel Technologies Ltd.
This page
|
500,000 | $37,070,000 | |
| 6 | RZLT |
Rezolute, Inc.
|
6,300,000 | $32,760,000 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
535,000 | $29,392,900 | |
| 8 | IMMX |
Immix Biopharma, Inc.
|
2,345,000 | $24,176,950 |
All Filings in SLGL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $37,070,000 | 500,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $39,610,000 | 500,000 | Shares | Sole | 2026-05-15 | |
| 2026-02-13 | $30,934,512 | 460,335 | Shares | Sole | 2026-03-23 | |
| 2025-12-31 | $19,120,561 | 453,739 | Shares | Sole | 2026-04-13 | |
| 2025-11-13 | $13,069,081 | 367,367 | Shares | Sole | 2025-11-17 | |
| 2025-09-30 | $5,970,940 | 204,835 | Shares | Sole | 2025-11-14 | |
| 2025-09-30 | $5,970,940 | 204,835 | Shares | Sole | 2025-11-14 | |
| 2025-08-22 | $3,159,880 | 139,386 | Shares | Sole | 2025-08-29 | |
| No filing history on record for this holder in this stock. | ||||||